Advertisement


Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement



Nov
28
Today In Oncology
Presence of Tumor-Infiltrating Lymphocytes Following Neoadjuvant Treatment May Contribute to Worse Survival in Patients With HER2-Positive Breast Cancer
Intraoperative Ultrasound vs Wire Localization in Surgery for Ductal Carcinoma in Situ
Effect of Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Patients Aged 70 and Older Receiving Treatment for Advanced Cancer
5-Year Outcomes With Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma
5-Year Survival and Cure Fraction Estimates for Childhood Cancer in Europe From 2000 to 2014 EUROCARE-6
View More 
Advertisement
© 2022 HSP News Service, L.L.C.
Designed by Harborside